Healthcare-associated Gram-negative market to be worth $3.6 billion by 2026; report

The global marketplace for healthcare-associated infections (HAIs) caused by Gram-negative bacteria across the seven major pharmaceutical markets (USA, 5EU (France, Germany, Italy, Spain, and the UK) and Japan.) is projected to exceed $3.6 billion in sales by 2026, at a compound annual growth rate (CAGR) of 10.8% from 2016 to 2026.

According to business information and analytics firm GlobalData’s latest report, ‘PharmaPoint: Healthcare-Associated Gram-Negative Infections – Global Drug Forecast and Market Analysis to 2026’ market growth will be dominated by the launch of multiple pipeline products, which will contribute a combined 73% of the sales across the 7MM in 2026.

Due to the lack of novel scaffolds being developed over the last few decades and limited investments into antibiotic R&D in recent years, the prevalence of resistant Gram-negative bacteria, especially in the hospital setting, has increased significantly; antibiotic resistance is now considered a major threat to the life expectancy of current and future generations.